ALLMedicine™ Central Retinal Vein Occlusion Center
Research & Reviews 378 results
https://clinicaltrials.gov/ct2/show/NCT04444492
May 11th, 2022 - Retinal vein occlusion (RVO) is the second most common retinal vascular disease leading to visual impairment. Main cause for visual impairment in CRVO (Central Retinal Vein Occlusion) is macular edema (ME) while neovascularization of the retina an...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022314
Journal of Medical Case Reports; Jürgens L, Yaici R et. al.
Apr 23rd, 2022 - Retinal arterial occlusive events in young patients are rare. However, because of physiological multifactorial adaptations during pregnancy, retinal vascular occlusive disease may occur spontaneously. In addition, a patent foramen ovale is a risk ...
https://doi.org/10.1007/s10792-022-02256-y 10.1001/archopht.1984.01040030405011 10.1016/s2214-109x(13)70145-1 10.1038/eye.2011.92 10.3310/hta19780 10.1016/j.drudis.2019.04.009 10.1021/acs.molpharmaceut.5b00775 10.1007/s00417-015-3130-z 10.1186/1478-7547-6-12 10.7326/m13-0768 10.1016/j.clinthera.2012.01.005 10.1023/a:1021171000838 10.1016/S0039-6257(02)00457-5 10.1016/s0008-4182(00)80077-0 10.1016/s0002-9394(99)00146-4 10.1001/archopht.118.1.47 10.1186/s12962-016-0056-1 10.1136/bjophthalmol-2011-300726 10.1586/14737167.5.3.245 10.1177/0272989x9301300404 10.1186/s12886-017-0514-3 10.1016/j.ophtha.2008.07.018 10.1111/aos.13185 10.1258/135763303769211337 10.15171/ijhpm.2015.173 10.1186/s12939-016-0374-0 10.1055/s-0043-109242 10.3111/13696998.2014.909435 10.1016/j.ajo.2016.09.012 10.1001/jamaophthalmol.2017.6565 10.1016/j.oret.2020.09.017
International Ophthalmology; Voutsas NT, Papageorgiou E et. al.
Apr 14th, 2022 - Neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), and macular oedema due to central retinal vein occlusion (CRVO) are leading causes of vision loss, currently managed with anti-vascular endothelial growth factor i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994389
BMC Ophthalmology; Wang YC, Li RR et. al.
Apr 10th, 2022 - To study the short-term change of macular function and the correlates after intravitreal conbercept for CRVO-ME. Prospective, clinical study. Twenty Three patients(23 eyes) were recruited, who were non-ischemia central retinal vein occlusion diagn...
https://doi.org/10.1097/IAE.0000000000003498
Retina (Philadelphia, Pa.); Martin-Gutierrez MP, Vermeirsch S et. al.
Apr 8th, 2022 - In previous landmark studies on central retinal vein occlusion (CRVO), retinal non-perfusion assessments were obtained using 7-field (7F) angiography. The widespread current use of widefield (WF) imaging allows better visualization of the peripher...
Drugs 1 results see all →
Clinicaltrials.gov 29 results
https://clinicaltrials.gov/ct2/show/NCT04444492
May 11th, 2022 - Retinal vein occlusion (RVO) is the second most common retinal vascular disease leading to visual impairment. Main cause for visual impairment in CRVO (Central Retinal Vein Occlusion) is macular edema (ME) while neovascularization of the retina an...
https://clinicaltrials.gov/ct2/show/NCT03810313
Jan 19th, 2022 - Following a 4-week maximum screening period, patients will be randomized and treated for approximately 76 weeks. Treatment visits will be scheduled in 4-week intervals. After 6 initial monthly injections of brolucizumab or aflibercept (loading pha...
https://clinicaltrials.gov/ct2/show/NCT04707625
Jan 6th, 2022 - Ten patients, 5 with branch retinal vein occlusion and 5 with central retinal vein occlusion, will receive stand of care anti-vascular endothelial growth factor over the course of 52 weeks while undergoing a paracentesis prior to each treatment. D...
https://clinicaltrials.gov/ct2/show/NCT03981549
Sep 13th, 2021 - The goal of this phase I/II prospective, randomized, sham-controlled, double-masked clinical trial is to determine whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from c...
https://clinicaltrials.gov/ct2/show/NCT04812977
Mar 24th, 2021 - To compare the effect of intravitreal-Bevacizumab and Triamcinolone with intravitreal-Bevacizumab alone on visual acuity and central foveal thickness in patients with macular edema secondary to central retinal vein occlusion.
News 38 results
https://www.medscape.com/viewarticle/913006
May 14th, 2019 - The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron) injection solution to treat all stages of diabetic retinopathy, the manufacturer has announced. Aflibercept, a vascular endothelial growth factor (VEGF) inhibito...
https://www.staging.medscape.com/viewarticle/913006
May 14th, 2019 - The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron Pharmaceuticals) injection solution to treat all stages of diabetic retinopathy, the manufacturer has announced. Aflibercept, a vascular endothelial growth factor...
https://www.medpagetoday.com/ophthalmology/generalophthalmology/69384
Nov 19th, 2017 - Development of technologies for sustained drug delivery is a topic of great interest among retina specialists, considering the number of chronic conditions that are managed with repeated intravitreal injections. Products in this category are alrea...
https://www.medscape.com/viewarticle/882951_2
Jul 24th, 2017 - Case Diagnosis Isolated chronic elevation of the optic disc with relatively preserved visual function raises suspicion for vitreopapillary traction (VPT). This diagnosis can be confirmed by OCT, as it was in this patient. Idiopathic intracranial h...
https://www.medscape.com/viewarticle/881454
Jun 20th, 2017 - Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial Scott IU, VanVeldhuisen PC, Ip MS, et al; SCORE2 Investigator Group JAMA. 2017; 317...
